JPC Global Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: JPC Global Pharmaceutical Export Portfolio Dataset — 6 Products, $286.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

JPC Global — Pharmaceutical Exporter Profile (2026) | 6 Products, $286.9K Trade | TransData Nexus

JPC Global

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $286.9K Total Trade · DGFT Verified

JPC Global is an Indian pharmaceutical exporter with a total trade value of $286.9K across 6 products in 4 therapeutic categories. Based on 132 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftazidime ($186.2K), Antitoxin ($31.5K), Tofacitinib ($22.9K).

JPC Global — Export Portfolio & Destination Treemap

JPC Global pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is JPC Global? — Company Overview & Market Position

JPC Global is an Indian pharmaceutical exporter specializing in the supply of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2015, the company is headquartered in New Delhi, India. It operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAD-3675. The firm's ownership structure comprises two designated partners: Rajat Juneja and Chandar Prakash Juneja. As of the latest available data, JPC Global has a total obligation of contribution of ₹10,000. The company has been active in the pharmaceutical industry for over eight years, focusing on the export of branded and contract-manufactured products. While specific revenue figures are not publicly disclosed, JPC Global has established a strong presence in the market, with a network of more than 300 distributors and authorized suppliers within India. The company's website, jpcglobal.co.in, provides further information on its products and services.

What Does JPC Global Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftazidime$186.2K 2

Product Portfolio — Top 6 by Export Value

JPC Global exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftazidime	Advanced Antibiotics	$186.2K	18	1.7%	9
2	Antitoxin	Other	$31.5K	14	0.2%	13
3	Tofacitinib	Advanced Oncology	$22.9K	36	0.6%	7
4	Ibrutinib	Advanced Oncology	$20.9K	23	2.1%	8
5	Vinblastine	Oncology	$17.8K	5	2.4%	12
6	Lomustine	Advanced Oncology	$7.6K	36	7.4%	3

JPC Global exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $286.9K. The top category is Advanced Antibiotics (64.9% of portfolio), followed by Advanced Oncology (17.9%), indicating a concentrated portfolio with the top 5 products accounting for 97.4% of total export value.

JPC Global — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

JPC Global operates a dedicated manufacturing plant that holds WHO Good Manufacturing Practice (GMP) certification. This facility specializes in the production of oncology products, including tablets, capsules, and injectables. The plant is equipped with state-of-the-art technology and contemporary machinery to ensure the highest quality standards in pharmaceutical manufacturing. While specific details regarding the plant's location and production capacities are not publicly disclosed, the company's commitment to quality is evident through its adherence to international manufacturing standards.

3Key Leadership

The leadership team at JPC Global comprises two designated partners:

Rajat Juneja: Appointed as a designated partner on June 12, 2015, Rajat has been associated with the company for over a decade, contributing to its strategic direction and growth.

Chandar Prakash Juneja: Joined as a designated partner on January 31, 2024, Chandar brings valuable experience to the leadership team, further strengthening the company's management.

The management team is dedicated to building lasting relationships with suppliers and clients, emphasizing timeliness and trust in all business operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does JPC Global Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

JPC Global's export portfolio includes six products across four therapeutic categories, with a total export value of $287,000 USD from 132 shipments. The top five products are:

Ceftazidime: $186,000 USD, Rank #9, 1.7% market share

Antitoxin: $31,000 USD, Rank #13, 0.2% market share

Tofacitinib: $23,000 USD, Rank #7, 0.6% market share

Ibrutinib: $21,000 USD, Rank #8, 2.1% market share

Vinblastine: $18,000 USD, Rank #12, 2.4% market share

The primary therapeutic categories include Advanced Antibiotics (64.9%), Advanced Oncology (17.9%), and Other (11.0%). Despite the significant export value, JPC Global does not hold a market leadership position in any of these categories. The company's portfolio is highly concentrated, with the top five products accounting for 97.4% of the total export value. This concentration indicates a strategic focus on specific high-value products, which may present both opportunities and risks in terms of market diversification and dependency.

JPC Global — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding JPC Global's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's focus on exporting finished pharmaceutical formulations suggests that it may engage in regulatory processes pertinent to the markets it serves. However, without explicit information, it is challenging to assess the extent of JPC Global's compliance with FDA regulations.

2WHO & EU GMP

JPC Global operates a manufacturing plant that holds WHO Good Manufacturing Practice (GMP) certification, indicating adherence to international manufacturing standards. However, specific details regarding EU GMP certification or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed. The company's commitment to quality is evident through its WHO GMP certification, which may facilitate access to various international markets.

3CDSCO & Indian Regulatory

JPC Global — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

JPC Global operates in a competitive landscape, focusing on the export of finished pharmaceutical formulations, particularly in the therapeutic categories of Advanced Antibiotics and Advanced Oncology. While specific competitors are not identified, the company's emphasis on specialty medicines and its extensive product database position it to compete effectively in these segments. The high concentration of export value in the top five products (97.4%) indicates a strategic focus, which may influence its competitive positioning. To enhance its market share and competitiveness, JPC Global may consider diversifying its product portfolio and exploring additional therapeutic areas.

2Key Differentiators

JPC Global's key differentiators include its extensive product database of over 1,000 specialty medicines, enabling it to meet the pharmaceutical needs of various markets, particularly in cases of rare illnesses or product unavailability. The company's WHO GMP-certified manufacturing facility underscores its commitment to quality and adherence to international manufacturing standards. Additionally, JPC Global's focus on building lasting relationships with suppliers and clients, emphasizing timeliness and trust, enhances its reputation in the industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating JPC Global as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

JPC Global has established a robust network of over 300 distributors and authorized suppliers within India, reflecting its strong presence in the domestic

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — JPC Global

How many pharmaceutical products does JPC Global export from India?

JPC Global exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Ceftazidime ($186.2K), Antitoxin ($31.5K), Tofacitinib ($22.9K), Ibrutinib ($20.9K), Vinblastine ($17.8K). Total export value is $286.9K.

What is JPC Global's total pharmaceutical export value?

JPC Global's total pharmaceutical export value is $286.9K, based on 132 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does JPC Global cover?

JPC Global exports across 4 therapeutic categories. The largest are Advanced Antibiotics (64.9%, 1 products), Advanced Oncology (17.9%, 3 products), Other (11.0%, 1 products).

Get Full JPC Global Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.